Awakn Life Sciences (TSE:AWKN) has released an update.
Awakn Life Sciences Corp., a biotech firm advancing treatments for substance use and mental health disorders, has announced a collaboration with Graft Polymer to enhance its trauma-focused Aminoindane NCEs program. This partnership aims to speed up the development of new therapies for mental health conditions like PTSD, leveraging Graft’s drug delivery systems and both companies’ shared expertise and financial investment.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.